They are not going to take a drug to market. They don't have either the manufacturing facilities or the marketting expertise.
The question is whether or not they will partner for P III. IF they take it through P III themselves and IF it is successfull then they can auction the rights with a much higher starting point then if they look for a partner now. On the other hand, a P III partner would spread the risk and reduce their cost.
Agreed. ASTX and Manuso aren't idiots.. Worth waaay more after Phase III.. As long as Dacogen revenues don't drop off the cliff, they we be able to afford their somewhat massive pipeline and get SGI thru Phase III